Sirigen, a company providing polymer dyes for application in technologies such as flow cytometry, has been acquired by manufacturer and global supplier of medical instruments, devices and reagents, Becton, Dickinson and Company (BD).
The polymer technology adopted by Sirigen has its premise in a Nobel-prize winning research carried out on conducting plastics. The technology enables the creation of unique dyes that are superior to traditional dyes by being four to ten times brighter. This characteristic is deemed to be a significant breakthrough in the field of polymers.
Alberto Mas, President at BD Biosciences, stated that the acquisition would serve as a complement to the company’s reagent platform and instruments portfolio. He also stated that the acquisition will help BD to continue the development of antibody specificity releases and innovative dyes over the next two years in order to augment the life science research reagent product line with highly effective products.
William A. Kozy, Executive Vice President at BD, offered his opinion on the acquisition saying that the investment in the novel technology would facilitate BD to differentiate its reagent portfolio. While the financial conditions of the acquisition have not been divulged, the acquisition is expected to result in a dilution of earnings per share for 2012 by US $0.01 on the basis of GAAP.
Founded in 1897, BD manufactures and markets instrument systems, medical devices and reagents and is committed to enchaining people's health across the globe. The company is headquartered in Franklin Lakes, New Jersey.
Source: http://www.bd.com/